临床药理学中的有效半衰期。 - Suppr

Suppr

超能文献

Effective half-life in clinical pharmacology.

作者信息

Boxenbaum H, Battle M

机构信息

Wyeth-Ayerst Research, Philadelphia, Pennsylvania 19101, USA.

出版信息

J Clin Pharmacol. 1995 Aug;35(8):763-6. doi: 10.1002/j.1552-4604.1995.tb04117.x.

DOI:10.1002/j.1552-4604.1995.tb04117.x

PMID:8522631

Abstract

摘要

相似文献

Effective half-life in clinical pharmacology.临床药理学中的有效半衰期。

J Clin Pharmacol. 1995 Aug;35(8):763-6. doi: 10.1002/j.1552-4604.1995.tb04117.x.

Inhibition of human aldose and aldehyde reductases by non-steroidal anti-inflammatory drugs.非甾体抗炎药对人醛糖还原酶和醛还原酶的抑制作用。

Adv Exp Med Biol. 1999;463:493-9. doi: 10.1007/978-1-4615-4735-8_62.

The molecular basis for inhibition of sulindac and its metabolites towards human aldose reductase.舒林酸及其代谢物抑制人醛糖还原酶的分子基础。

FEBS Lett. 2012 Jan 2;586(1):55-9. doi: 10.1016/j.febslet.2011.11.023. Epub 2011 Dec 8.

Pharmacokinetics of the aldose reductase inhibitor tolrestat: studies in healthy young and elderly male and female subjects and in subjects with diabetes.

Clin Pharmacol Ther. 1996 Jun;59(6):603-12. doi: 10.1016/S0009-9236(96)90000-4.

Structural analysis of sulindac as an inhibitor of aldose reductase and AKR1B10.舒林酸作为醛糖还原酶和AKR1B10抑制剂的结构分析

Chem Biol Interact. 2015 Jun 5;234:290-6. doi: 10.1016/j.cbi.2014.12.018. Epub 2014 Dec 20.

Pharmacodynamics and pharmacokinetics of topical adapalene.外用阿达帕林的药效学与药代动力学。

J Am Acad Dermatol. 1998 Aug;39(2 Pt 3):S17-24. doi: 10.1016/s0190-9622(98)70440-2.

An old NSAID revisited: crystal structure of aldose reductase in complex with sulindac at 1.0 Å supports a novel mechanism for its anticancer and antiproliferative effects.一种旧的非甾体抗炎药的新发现：醛糖还原酶与舒林酸复合物在1.0 Å分辨率下的晶体结构支持其抗癌和抗增殖作用的新机制。

ChemMedChem. 2011 Dec 9;6(12):2155-7. doi: 10.1002/cmdc.201100374. Epub 2011 Oct 13.

Efficacy and safety of nonsteroidal anti-inflammatory drugs in the therapy of diabetic neuropathy.非甾体抗炎药治疗糖尿病性神经病变的疗效与安全性

Arch Intern Med. 1987 Aug;147(8):1442-4.

Absorption of sulindac from a novel (Pro-SorbTM) liquid formulation.

Biopharm Drug Dispos. 1996 Apr;17(3):209-21. doi: 10.1002/(SICI)1099-081X(199604)17:3<209::AID-BDD956>3.0.CO;2-6.

Pharmacokinetics and dialyzability of sulindac and metabolites in patients with end-stage renal failure.终末期肾衰竭患者中舒林酸及其代谢产物的药代动力学和可透析性

J Clin Pharmacol. 1993 Jun;33(6):527-34. doi: 10.1002/j.1552-4604.1993.tb04699.x.

引用本文的文献

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria.培格西他单抗在阵发性睡眠性血红蛋白尿症患者中的群体药代动力学及药代动力学/药效学分析。

Drugs R D. 2024 Dec;24(4):563-573. doi: 10.1007/s40268-024-00500-7. Epub 2024 Nov 29.

Evaluation of Effective Half-Life and Its Impact on Time to Steady State for Oral MeltDose Tacrolimus (LCPT) in De Novo Kidney Transplant Recipients.对初发肾移植受者口服溶融剂型他克莫司（LCPT）的有效半衰期及其对达到稳态时间的影响进行评估。

Ther Drug Monit. 2025 Feb 1;47(1):169-173. doi: 10.1097/FTD.0000000000001270. Epub 2024 Oct 24.

Population Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients with Breast Cancer or Colorectal Cancer.曲妥珠单抗在健康参与者和乳腺癌或结直肠癌患者中的群体药代动力学分析。

Clin Pharmacokinet. 2024 Oct;63(10):1477-1487. doi: 10.1007/s40262-024-01412-0. Epub 2024 Oct 5.

Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors.口服 PD-L1 抑制剂 GS-4224 选择性结合 PD-L1 高表达细胞，并在晚期实体瘤患者中引发药效学反应。

J Immunother Cancer. 2024 Apr 11;12(4):e008547. doi: 10.1136/jitc-2023-008547.

Pharmacokinetics of Glepaglutide, A Long-Acting Glucagon-Like Peptide-2 Analogue: A Study in Healthy Subjects.格列帕鲁肽的药代动力学：一项在健康受试者中的研究。

Clin Drug Investig. 2022 Dec;42(12):1093-1100. doi: 10.1007/s40261-022-01210-1. Epub 2022 Nov 2.

Clinical Pharmacokinetic Assessment of Kratom (), a Botanical Product with Opioid-like Effects, in Healthy Adult Participants.对具有阿片样作用的植物产品 kratom（）在健康成年参与者中的临床药代动力学评估。

Pharmaceutics. 2022 Mar 11;14(3):620. doi: 10.3390/pharmaceutics14030620.

Navigating the Novel Psychotropics.探索新型精神药物

Focus (Am Psychiatr Publ). 2021 Jan;19(1):1-2. doi: 10.1176/appi.focus.20200044. Epub 2021 Jan 25.

Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia.精神分裂症受试者乌洛托品的群体药代动力学分析。

CPT Pharmacometrics Syst Pharmacol. 2021 Oct;10(10):1245-1254. doi: 10.1002/psp4.12692. Epub 2021 Aug 10.

Current Bioequivalence Study Designs in South Korea: A Comprehensive Analysis of Bioequivalence Study Reports Between 2013 and 2019.韩国当前的生物等效性研究设计：对2013年至2019年生物等效性研究报告的综合分析

Front Pharmacol. 2021 May 4;12:651790. doi: 10.3389/fphar.2021.651790. eCollection 2021.

First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors.MP0250 是一种靶向 VEGF 和 HGF 的首创类 DARPin 药物候选物，在晚期实体瘤患者中的首次人体 I 期研究。

J Clin Oncol. 2021 Jan 10;39(2):145-154. doi: 10.1200/JCO.20.00596. Epub 2020 Dec 10.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验